Answers are grounded in this paper and cite their sources.
We examined colorectal cancer screening and subsequent care in four communities within a hospital-led medical consortium in Kunshan, China. This retrospective cohort study linked 2023–2025 screening records for residents aged 40–74 years with colonoscopy, pathology and subsequent-care records. The main outcome was documented colonoscopy after the earliest dated positive questionnaire or fecal immunochemical test (FIT), without a 180-day limit. Among 12,388 residents, 4,000 had a dated positive screen and 867 had a subsequent colonoscopy record (21.7%, 95% confidence interval 20.4–23.0%), including 64 beyond 180 days. Annual proportions were 20.8%, 20.2% and 26.6%. The adjusted odds ratio for 2025 versus 2023 was 1.46 (1.08–1.97), with Holm-adjusted P = 0.018. In independent first-FIT-positive cohorts, annual proportions were 71.3%, 61.8% and 38.6%. The wider clinical series comprised 999 colonoscopy recipients, including 14 with recorded cancer and 336 with adenoma or high-grade dysplasia without recorded cancer. Pathology was unavailable for 384, and later examination findings were recorded for 54. These records describe differences in diagnostic assessment and subsequent care across communities and years. Incomplete report retrieval and unequal observation time limit their interpretation.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: